A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggested big pharma may finally be willing to place ...

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results CEO Yvonne Greenstreet ...

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

The vaccine maker’s board intends to recommend a pending offer from investment firms Nordic Capital and Permira, which would ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA ...

The abrupt exit of the former CBER director raises questions about the FDA’s leadership. For now, newly appointed CDER head ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...